

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM780782

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
PhaseBio Pharmaceuticals, Inc.		01/13/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	SFJ Pharmaceuticals X, Ltd.		
<b>Street Address:</b>	C/O SFJ PHARMACEUTICALS X, L.P., 5000 HOPYARD ROAD		
<b>Internal Address:</b>	SUITE 330		
<b>City:</b>	PLEASANTON		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94588		
<b>Entity Type:</b>	Company: CAYMAN ISLANDS		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90808336	OPMIZTA	
<b>Serial Number:</b>	90808332	RETRIG	
<b>Serial Number:</b>	90808334	XYFT	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2124796275		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2124796000		
<b>Email:</b>	vcaba@cooley.com		
<b>Correspondent Name:</b>	Cooley LLP		
<b>Address Line 1:</b>	1299 Pennsylvania Avenue, NW, Suite 700		
<b>Address Line 2:</b>	Attn: Veronica Caba		
<b>Address Line 4:</b>	Washington, D.C. 20004		
<b>ATTORNEY DOCKET NUMBER:</b>	309646.20000		
<b>NAME OF SUBMITTER:</b>	Veronica Caba		
<b>SIGNATURE:</b>	/VC/		
<b>DATE SIGNED:</b>	01/13/2023		
<b>Total Attachments: 12</b>			

CH \$90.00 90808336

source=SFJ-PB - Trademark Assignment Agreement (Executed)#page1.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page2.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page3.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page4.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page5.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page6.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page7.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page8.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page9.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page10.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page11.tif  
source=SFJ-PB - Trademark Assignment Agreement (Executed)#page12.tif

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT (this “Agreement”) is made and entered into as of January 13, 2023 (the “Effective Date”), by and between PhaseBio Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to as “Assignor”), and SFJ Pharmaceuticals X, Ltd., a Cayman Islands company (hereinafter referred to as “Assignee”). Assignor and Assignee are each referred to individually as a “Party”, and together as the “Parties”.

WHEREAS, Assignor holds all right, title and interest in and to those certain trademarks identified on Appendix 1 attached hereto (the “Assigned Trademarks”);

WHEREAS, Assignor and Assignee are parties to that certain Program Transfer Agreement, dated as of January 13, 2023 (the “Program Transfer Agreement”), pursuant to which Assignor has agreed to sell, assign, transfer, convey and deliver, or cause to be sold, assigned, transferred, conveyed and delivered, to SFJ the Acquired Assets, which Acquired Assets include the Assigned Trademarks, subject to the terms and conditions set forth in the Program Transfer Agreement;

WHEREAS, pursuant to the Program Transfer Agreement, in consideration for Assignor’s sale, assignment, transfer, conveyance and delivery of the Acquired Assets and Assignor’s other obligations thereunder, Assignee has agreed to certain payment and royalty obligations as set forth in Section 3 of the Program Transfer Agreement; and

WHEREAS, subject to the terms and conditions set forth in the Program Transfer Agreement, the Parties wish to enter into this Agreement for the assignment of the Assigned Trademarks from Assignor to Assignee and to effectuate the transfer of the Assigned Trademarks from Assignor to Assignee.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the Parties, intending to be legally bound, hereby agree as follows:

1. Definitions. Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to such terms as set forth in the Program Transfer Agreement.

2. Assignment. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in accordance with and subject to the provisions of the Program Transfer Agreement and this Agreement, Assignor hereby irrevocably sells, assigns, transfers, conveys and delivers to Assignee, and Assignee hereby acquires, all of Assignor’s right, title and interest in and to the following:

(a) the Assigned Trademarks and all issuances, extensions, and renewals thereof, together with the goodwill of the business connected with the use of, and symbolized by, the Assigned Trademarks;

(b) all rights of any kind whatsoever of Assignor accruing under any of the Assigned Trademarks provided by applicable Law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world;

(c) any and all royalties, fees, income, payments, and other proceeds, in each case, now or hereafter due or payable with respect to any and all of the foregoing; and

(d) any and all claims and causes of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, dilution, misappropriation, violation, misuse, breach, or default, with the right but no obligation to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.

3. Recordation and Further Actions. Assignor hereby authorizes and requests that the Commissioner for Trademarks in the United States Patent and Trademark Office, and any other sovereign official of a corresponding entity or agency in any applicable jurisdiction, to record and register this Agreement upon request by Assignee. Following the date hereof, upon Assignee's reasonable request, and at Assignor's sole cost and expense, Assignor shall take such reasonable steps and actions and provide such reasonable cooperation and assistance to Assignee and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be necessary to effect, evidence, or perfect the assignment of the Assigned Trademarks to Assignee.

4. Counterparts. This Agreement may be executed in one or more counterparts (including by facsimile and electronic transmission), each of which when executed will be deemed to be an original, but all of which taken together will constitute one and the same agreement.

5. Governing Law. This Agreement and all matters arising out of or relating to this Agreement will be governed by, and construed in accordance with, the Laws of the State of Delaware applicable to contracts executed in and to be performed entirely within such State, without giving effect to the principles of conflict of Laws that would require or permit the application of the Laws of any other jurisdiction. To the extent that it may otherwise be applicable, the Parties hereby expressly agree to unconditionally waive and exclude from the operation of this Agreement the United Nations Convention on Contracts for the International Sale of Goods, concluded at Vienna, on 11 April 1980, as amended and as may be amended further from time to time. This Agreement has been negotiated and drafted by the Parties in the English language. Any translation into any other language shall not be an official version thereof. In the event any translation of this Agreement is prepared for convenience or for any other purpose, the provisions of the English version shall prevail.

6. Terms of the Program Transfer Agreement. Notwithstanding anything in this Agreement to the contrary, the sale, assignment, transfer, conveyance and delivery effectuated hereby is subject in all respects to the terms and conditions of the Program Transfer Agreement and nothing in this Agreement, express or implied, is intended or shall be construed to alter, expand or defeat, impair or limit in any way the representations and warranties nor the rights, obligations, claims or remedies of Assignor or Assignee as set forth in the Program Transfer Agreement.

7. Assignment to Third Party. Neither this Agreement nor any of the rights, interests, or obligations under this Agreement shall be assigned or otherwise transferred, in whole or in part, by Assignor to any third party without the prior written consent of Assignee. Except as expressly provided in this Section 7, any purported assignment or other transfer without such consent will be void and unenforceable. Subject to this Section 7, this Agreement will be binding upon, inure to the benefit of, and be enforceable by the Parties and their respective successors and assigns. No waiver of any term, condition, or obligation of this Agreement shall be valid unless in writing and signed by the waiving Party. No waiver of any one or several of the terms, conditions or obligations of this Agreement, and no partial waiver thereof, shall be construed as a waiver of any of the other terms, conditions, or obligations of this Agreement.


8. Severability. In the event that any one or more of the terms or provisions contained in this Agreement or in any other certificate, instrument, or other document referred to in this Agreement, will, for any reason, be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other term or provision of this Agreement or any other such certificate, instrument, or other document referred to in this Agreement, and the Parties will use their commercially reasonable efforts to substitute one or more valid, legal, and enforceable terms or provisions into this Agreement which, insofar as practicable, implement the purposes and intent of this Agreement. Any term or provision of this Agreement held invalid or unenforceable only in part, degree, or within certain jurisdictions will remain in full force and effect to the extent not held invalid or unenforceable to the extent consistent with the intent of the Parties as reflected by this Agreement. To the extent permitted by applicable Law, each Party waives any term or provision of Law which renders any term or provision of this Agreement to be invalid, illegal, or unenforceable in any respect.

*[Remainder of Page Intentionally Left Blank]*

IN WITNESS WHEREOF, each of the undersigned, intending to be legally bound hereby, has duly executed this Agreement as of the Effective Date.

PHASEBIO PHARMACEUTICALS, INC.

SFJ PHARMACEUTICALS X, LTD.

By:  \_\_\_\_\_

By: \_\_\_\_\_

Name: Jonathan Mow

Name:

Title: Chief Executive Officer

Title:

*[Signature Page to Trademark Assignment Agreement]*

**TRADEMARK**  
**REEL: 007946 FRAME: 0611**

IN WITNESS WHEREOF, each of the undersigned, intending to be legally bound hereby, has duly executed this Agreement as of the Effective Date.

PHASEBIO PHARMACEUTICALS, INC.

SFJ PHARMACEUTICALS X, LTD.

By: \_\_\_\_\_

By: Robert DeBenedetto

Name:

Name: Robert DeBenedetto

Title:

Title: Director

[Signature Page to Trademark Assignment Agreement]

## **APPENDIX 1**

### **Assigned Trademarks**

See attached.



# Appendix 1

MARK	COUNTRY	APPL. NO.	REG. NO	REG. DATE	CLASS	GOODS AND SERVICES
OPMIZTA	United States	90808336			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	United States	90808332			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
XYFT	United States	90808334			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Australia (via Madrid Protocol)	1644188	1644188	27 Apr 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Brazil (via Madrid Protocol)	1644188			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in

**TRADEMARK**

						major bleeding and urgent surgery situations
RETRIG	Canada (via Madrid Protocol)	2165742			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	China (via Madrid Protocol)	1644188	1644188	14 Jun 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	European Union (via Madrid Protocol)	1644188	1644188	30 Jun 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
REYTRIG	European Union	018722811	018722811	3 Nov 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

RETRIG	India (via Madrid Protocol)	5327783			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Japan (via Madrid Protocol)	1644188			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Madrid Protocol  Designated Jurisdictions: Australia, Brazil, Canada, China, European Union, India, Japan, Norway, Russia, South Korea, Switzerland, Turkey, and United Kingdom	1644188	1644188	10 Feb 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Norway (via Madrid Protocol)	202201993			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations

REYTRIG	Norway	202208914	323374	26 Aug 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Russia (via Madrid Protocol)	1644188	1644188	23 May 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
REYTRIG	Russia	2022742303	909491	8 Dec 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	South Korea	1644188			05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Switzerland (via Madrid Protocol)	1644188	1644188	30 Dec 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations

REYTRIG	Switzerland	085032022	790198	4 Dec 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
RETRIG	Turkey	1644188	1644188	1 Dec 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
REYTRIG	Turkey	2022093097	2022093097	5 Oct 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations
EURETRIG	United Kingdom	3737383	3737383	1 Apr 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
RETRIG	United Kingdom (via Madrid Protocol)	1644188	1644188	26 Apr 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations

REYTRIG	United Kingdom	3737380	3737380	1 Apr 2022	05	Class 05: Pharmaceutical preparation, namely, a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
---------	----------------	---------	---------	------------	----	---